Close Menu

stock repurchase

The company recently changed its name from Expedeon following the sale of its immunology and proteomics businesses to Abcam.

The company also announced that its board of directors has authorized payment of a quarterly cash dividend of $0.04 per share of its common stock.

Qiagen also announced plans to launch a new $100 million share repurchase program after completing its current $200 million share repurchase commitment.

The company has entered into an accelerated share repurchase program with the bank to buy back a portion of its common stock.

The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.

Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.

The repurchase is part of a commitment announced by the company in July 2016 to return $300 million to shareholders by the end of 2017.

Qiagen plans to return about $250 million to shareholders through a program that combines a direct capital repayment with a reverse stock split.

Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.

As of the end of its fiscal third quarter of 2016, Myriad had repurchased more than $1.1 billion of stock since the inception of the buyback program in 2010.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.